bioRxivPharmacology & ToxicologyPreprint
Assessment of non-linear mixed effects model-based approaches to test for drug effect using simulated data: type I error and power properties
Abstract
1Pharmacometric approaches achieves higher power to detect a drug effect compared to traditional statistical hypothesis tests. Known drawbacks come from the model building process where multiple testing and model misspecification are major causes for type I error inflation. IMA is a new approach using mixture models and the likelihood ratio test (LRT) to test for drug effect. It previously showed type I error control and unbiased drug estimates in the context of two-arms balanced designs using real placebo data, in comparison to the standard approach (STD). The aim of this study was to extend the assessment of IMA and STD regarding type I error, power, and bias in the drug effect estimates under various types of model misspecification, with or without LRT calibration. Two classical statistical approaches, t-test and Mixed-Effect Model Repeated Measure (MMRM), were also added to the comparison. The focus was a simulation study where the extent of the model misspecification is known, using a response model with or without drug effect as motivating example in two sample size scenarios. The IMA performances were overall not impacted by the sample size or the LRT calibration, contrary to STD which had better type I error results with the larger sample size and calibrated LRT. In terms of power STD required LRT calibration to outperform IMA. T-test and MMRM had both controlled type I error. The t-test had a lower power than both STD and IMA while MMRM had power predictions similar to IMA. IMA and STD had similarly unbiased drug effect estimates, with few exceptions. IMA showed again encouraging performances (type I error control and unbiased drug estimates) and presented reasonable power predictions. The IMA performances were overall more robust towards model mis-specification compared to STD. IMA confirmed its status of promising NLMEM-based approach for hypothesis testing of the drug effect and could be used in the future, after further evaluations, as primary analysis in confirmatory trials.
- research focus: drug response / drug discovery
- research focus: benchmarking
- research focus: variant effect prediction
- approach: statistical model
- approach: simulation
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Extension of individual model averaging assessments to unbalanced designs and dose-response
E. Chasseloup, X. Li, M. O. Karlsson·bioRxiv·Apr 13, 2024
- Trimmed Constrained Mixed Effects Models: Formulations and Algorithms.
Peng Zheng, Ryan M Barber, … Aleksandr Y. Aravkin·Journal of Computational and Graphical StatisticsPeer-reviewed·Jan 4, 2021
- Dirac mixture distributions for the approximation of mixed effects models
Dantong Wang, Paul L. Stapor, Jan Hasenauer·IFAC-PapersOnLinePeer-reviewed·Jan 1, 2019
- Statistical power and false positive rates for interdependent outcomes are strongly influenced by test type: Implications for behavioral neuroscience
Michelle A. Frankot, Peyton M. Mueller, … Cole Vonder Haar·NeuropsychopharmacologyPeer-reviewed·May 4, 2023
- Mixed Model with Correction for Case-Control Ascertainment Increases Association Power
tristan hayeck, Noah Zaitlen, … Alkes Price·The American Journal of Human GeneticsPeer-reviewed·May 1, 2015
- Upstrap for estimating power and sample size in complex models
M. Karas, C. Crainiceanu·bioRxiv·Aug 21, 2021